A TWO-WEEKS CONSUMER PERCEPTION STUDY TO EVALUATE A HAIR DRYER PERFORMACE

FINAL REPORT

April 6, 2022

SPONSOR:	TH Genesis 122 Sheldon St. EL Segundo, CA
TEST PRODUCT:	SRI DryQ Hair Dryer
STUDY NUMBER:	21-01545
STUDY CODE:	IRSI-E-EP-21-01545-12-21

RESEARCH STANDARD

The conduct of this study complied with the Declaration of Helsinki principles, the applicable regulatory requirements and according to the Good Clinical Practices (Document of the Americas and ICH E6: Good Clinical Practice).

TABLE OF CONTENTS

I. SUMMARY OF RESULTS

Under conditions of the study, a total of 35 healthy female subjects completed the clinical study evaluating the effectiveness of Test Product: SRI DryQ Hair Dryer to improve hair conditions based on consumer perception.

A. Post-Treatment Questionnaire (Week 2)

Statement	% Favorable Response
1. The SRI DryQ cut my drying time by 1= 0%, 2= 25%, 3= 75%, 4= 100%	1= 5.71% 2= 37.14% 3= 45.71% 4= 11.43%
2. My hair feels softer after using the SRI DryQ	**80.00%**
3. My hair feels stronger after using the SRI DryQ	65.71%
4. My hair looks and feels fuller after using the SRI DryQ	**74.29%**
5. My scalp health improved after using the SRI DryQ	62.86%
6. I prefer the SRI DryQ over other hair dryers I've used in the past	**77.14%**
7. The SRI DryQ doesn't damage my hair like other hair dryers	**85.71%**
8. The SRI DryQ is quieter than other hair dryers I've tried in the past	**85.71%**
9. How likely would you be to suggest the SRI DryQ to friends and family? 1= Very Unlikely, 2= Not Likely, 3= Likely, 4= Very Likely	1= 2.86% 2= 5.71% 3= 28.57% 4= 62.86%
10. I feel more confident drying and styling my hair with the technology the SRI DryQ provides	**77.14%**
11. The SRI DryQ helps strengthens weak, brittle, damaged hair	**74.29%**
12. The SRI DryQ is easy to use compared to other hair dryers I've used	**82.86%**
13. The SRI DryQ gives my hair more volume than other hair dryers	**77.14%**
14. I feel more confident after using the SRI DryQ	**80.00%**
15. The foldable design makes traveling and storage more convenient than other dryers	**97.14%**

16. My hair is shinier after using the SRI DryQ	**74.29%**
17. I feel like I just stepped out of the salon after using the SRI DryQ	54.29%
18. I feel the SRI DryQ is a better product than other hair dryers I've used in the past.	**88.57%**
19. Drying my hair is fast and easy with the SRI DryQ	**91.43%**
20. The SRI DryQ is the best dryer I've ever used	65.71%

Bold values indicate statistical significance ($p \leq 0.05$).

II. STUDY OBJECTIVE

The objective of this study was to assess the investigational product efficacy, under normal use condition, through consumer perception using self-assessments questionnaires.

III. STUDY DATES

The study began on February 23, 2022 and ended on March 22, 2022.

IV. TESTING FACILITY

International Research Services, Inc.
222 Grace Church Street, Suite 204
Port Chester, NY 10573

V. TEST PRODUCTS

Test Product	Number of Samples	Date Received
SRI DryQ Hair Dryer	40	08Feb2022 & 09Feb2022

VI. TEST PRODUCT HANDLING

Investigational product were provided by the sponsor and were labeled with appropriate codes and proper use instructions. All products sent by the sponsor were initially stored in the samples room at the study site, with controlled temperature and restricted access. Products release was controlled by the principal investigator or by a previously designated technical staff.

A sample of each product will be cataloged, and it can be found in the institute's archive for a one-month period after the completion of the study.

Test Product Use Instructions

Make sure hands are completely dry before connecting the appliance to the mains. Connect the hair dryer and switch from OFF to ON. Adjust temperature to best meet your needs.

VII. ADVERSE EVENTS

No adverse events were reported during the study period.

VIII. PROTOCOL DEVIATIONS

No protocol deviations were recorded during the study period.

IX. SUBJECT DEMOGRAPHICS

A. Study Subjects

A total of 35 healthy female subjects consented, enrolled and completed the clinical study.

Table 1. Subject Demographics

Subject ID	Subject Initials	Age
001	ARN	21
002	KVD	23
003	JML	36
004	MAP	32
005	DMP	39
006	LMG	38
007	TLG	24
008	SLS	32
009	MMM	29
010	DRA	21
011	AVL	21
012	RAC	34
013	JLD	28
014	TTI	25
015	AMP	26
016	CJM	38
017	MTN	25
018	OEP	25
019	VMG	24
020	KLB	31
021	JNA	25
022	LAG	20
023	RLG	24
024	AKL	29
025	JAV	23
026	BS	32
027	LC	54
028	BDL	54
029	MO	41
030	KAD	26
031	SKD	19
032	DMD	25
033	EMD	21
034	NBB	34
035	JKD	20

APPENDIX A

A TWO-WEEKS CONSUMER PERCEPTION STUDY TO EVALUATE A HAIR DRYER PERFORMACE (21-01545)

STUDY PROJECT

TYPE OF INVESTIGATIONAL PRODUCTS: Hair Dryer
INVESTIGATIONAL PRODUCTS NAME: SRI DryQ Hair Dryer
PROJECT CODE: 21-01545_THG_Hair Dryer SAQ_V5.0

INVESTIGATIONAL PRODUCTS CODE: 21-01545
PROTOCOL NUMBER: IRSI-E-EP-21-01545-12-21-PRV01
STUDY CODE: IRSI-E-EP-21-01545-12-21

PROTOCOL DATE: 02/11/2022

SPONSOR: TH Genesis
122 Sheldon St, El Segundo CA USA
Telephone: (818)456-8918
Inquirer: Michael Armstrong

STUDY SITE: INTERNATIONAL RESEARCH SERVICES, INC.
222 Grace Church Street
Port Chester, NY 10573
Telephone: 914.937.6500
Principal Investigator: Nathalia Pereira de Souza
Coordinator: Jennifer Navatta

SUMMARY

The broad development of the cosmetics area has been encouraging researchers from the R&D field to make an effort towards developing safe, stable, effective and sensorially pleasing products. With this perspective, modern methodologies are being used to prove the benefits of the formulations and innovative devices that will be available on the market.

The study will be performed with a hair dryer device, with up to 35 study subjects who meet the inclusion and non-inclusion criteria required. Study subjects will be instructed to continue using their usual hair care products in addition with the use of the investigational product and follow a routine of use for 2 weeks. They will be assessed through at home self-assessment questionnaires.

INTRODUCTION

Over the last few years, the cosmetic industry has grown considerably, same as its concern in developing safe and effective products. Industry awareness and consumer's and regulatory agencies requirements caused cosmetic manufacturers to adopt procedures that lead them to know better their products: to conduct clinical tests on safety and efficacy, which are coordinated by expert physicians, before marketing a product. These procedures provide cosmetic companies with greater safety, credibility and reliability among their consumers.

Efficacy studies allow us to assess the product's characteristics, detecting complaints and comments regarding its performance, as well as testing the quality control and the assured quality, analysis of competitors and claims support (what the product offers). In order to evaluate if a claim is appropriate, it is necessary to take into account the general consumers' impression concerning the presentation or the product advertisement (COLIPA, 2008). The claims must be supported by solid, clear and relevant evidence. Such evidence may result from experimental studies (biochemical / instrumental methods, sensory evaluations, technical evaluations and evaluations without the participation of study subjects, in vitro testing in cell cultures, use of hair locks, etc.), and consumers evaluations (ASTM E 1958-06, 2006).

For the efficacy assessment of products, clinical and/or self-assessment studies and instrumental studies can be used. The Self-Assessment by the study subjects is performed by following the "Standard Guide for Sensory Claim Substantiation" (ASTM E 1958-06, 2006), by using questionnaires. The ASTM (American Society for Testing and Materials) standards organization has been developed for over a century and represents one of the greatest voluntary organizations for standards development in the world, being a reliable source of technical standards of material, products, systems and services. Known by their high technical quality and relevance on market, ASTM standards have an important role in the infrastructure of the information guiding the study design, product manufacturing and commerce in global economy. The "Standard Guide for Sensory Claim Substantiation" is an ASTM standard that aims to disclose the good practices in sensory studies, approaching reasonable practices for executing sensory studies to validate product claims.

HYPOTHESIS

It is expected that the use of the investigational product demonstrates an improving of the hair thickness, increases shine, reduces frizz, protects hair from heat damage and presents superior technical characteristics to products of the same category.

The promotion of these effects will be proven through self-assessment questionnaires.

OBJECTIVE

The objective of this study will be to assess the investigational product efficacy, under normal use condition, through the consumer perception using self-assessments questionnaires.

If the objective is achieved, the following claims will be supported:

Claims

Claims	Methodology
Cuts drying time in half	At Home Self- Assessment Questionnaire
Significantly reduces the drying time	
Improves hair thickness	
Increases Shine	
Leaves hair feeling soft	
Leaves hair looking shiny	
Hair feels stronger	
Hair feels healthier	
Reduces frizz	
Protects hair from heat damage	
The lightest hair dryer on the market (that I've ever tried!)	
Increases shine by a __% (list 0%, 25%,50%, 75%,100%)	
Quietest hair dryer on the market (that I've ever tried!)	
Improves hair texture	
Less split ends and breakage	

STUDY DESIGN

Non-comparative clinical study.

TEST SITE

The investigational product will be used on the study subjects' hair.

INVESTIGATIONAL AND SUPPORT PRODUCTS

Investigational product will be provided by the sponsor and will be labeled with appropriate codes and proper use instructions. All products sent by the sponsor will be initially stored in the samples room at the study site, with controlled temperature and restricted access. Products release will be controlled by the principal investigator or by a previously designated technical staff.

A sample of each product will be cataloged, and it can be found in the institute's archive for a one-month period after the completion of the study.

Identification

Investigational and support products identification

Product Name	Product Type	Study Product Code
SRI DryQ Hair Dryer	Hair dryer	21-01545

Investigational Product Use Instructions

The SRI DryQ Hair Dryer will be used following sponsor provided use instructions, exactly as follows: Make sure hands are completely dry before connecting the appliance to the mains. Connect the hair dryer and switch from OFF to ON. Adjust temperature to best meet your needs.

Products Use Compliance Check

The compliance of product use by the subjects will be checked through the diary of products use that will be completed by the subjects.

STUDY PERIOD

The study duration for each subject will be up to 2 weeks.

STUDY SUBJECTS

Study Subjects Recruitment

The study subjects will be recruited by the recruitment department of the study center. They are contacted and asked to take part in the selection process and if they meet all required criteria, they will be included in the study.

The study will be performed in IRSI facilities, and the subjects will be informed about the site/address when contacted.

Selection and Admission of Study Subjects

During the subjects' selection for the study, the Institute will certify that the subjects do not present pathologies that could interfere with the study results. IRSI is also responsible for checking all inclusion and non-inclusion criteria for admission of the subject in the study.

Study Population

In order to reach a number of 30 subjects, approximately 35 will be enrolled in the study.

Inclusion Criteria

1. Females in good general health, and between ages of 18 and 55 years old, inclusive at enrollment;
2. Subjects who blow dry and style hair at least three times a week;
3. Subjects willing to use their own routine hair products during the course of the study and not change any products for duration of the study;
4. Subjects using the same hair products for previous 30 days;
5. Subjects will be able to read, understand and sign an informed consent form (includes HIPAA and State requirements);
6. Subjects are willing and able to follow all study directions, attend study visits as scheduled and must be willing to accept the restrictions of the study;

Non-Inclusion Criteria

1. Subjects participating in any other clinical studies;
2. Subjects having an acute or chronic disease or medical condition, including dermatological problems, which could put her at risk in the opinion of the Principal Investigator or compromise study outcomes. Typical un-controlled chronic or serious diseases and conditions which would prevent participation in any clinical trial are cancer, AIDS, diabetes (insulin dependent, renal impairment, mental illness, drug/alcohol addiction;
3. Subjects who are unreliable or unlikely to be available for the duration of the study;
4. History of allergic reactions, skin sensitization and/or known allergies to cosmetic ingredients, toiletries, sunscreens, etc.;
5. Immunocompromised subjects;
6. Woman known to be pregnant, lactating or planning to become pregnant within six months. Subjects who become pregnant during the study must inform the Principal Investigator immediately;
7. Individuals unable to communicate or cooperate with the Principal Investigator due to language problems, poor mental development, or impaired cerebral function;
8. Employees of IRSI or other testing firms/ laboratories, cosmetic or raw goods manufacturers or suppliers.

METHODOLOGY

General procedures

a) Visit 01

Figure 1. On the initial visit (T0) the subjects will be informed about the study objective, its methodology and duration, also about the possibly expected benefits and constraints related to the study and signed the Informed Consent Form (ICF). A trained technician will confirm the inclusion and non-inclusion criteria. The subjects will receive the hair dryer and daily log. During this period, subjects will be instructed to record in the daily log all the uses performed and possible comments about the products.

Figure 2. After 2 weeks (T2w) of the investigational product use, subjects will answer at home a self-assessment questionnaire about the perception of the product.

b) Visit 02

Figure 3. They will return to the Institute only to return the hair dryer and the filled out daily log.

Figure 4. At both visits, subjects will remain at rest in a room for at least 15 minutes before the assessments.

Procedure Schedule

Study Schedule

Phases	**Visit 01**	**At home**	**Visit 02**
	T0	**T2w**	
Informed Consent Form signature	X	-	-
Inclusion/Non-inclusion Criteria	X	-	-
Dispense (D) and Collect (C): -Investigational product -Daily log	D	-	C
Self-assessment questionnaire	-	At home	-

Methods

Self-Assessment Questionnaire Performed by the Study Subjects

Subjective questionnaires allow the sponsor to gauge the subjects' perceptions of the investigational product and its effects. Questions that will be asked for subjects' agreement to a statement with a provided scale. Detailed time point, attributes and scale are described on the table below.

The questionnaires will be taken after 2 weeks of investigational product use.

Criteria and Procedures for Study Subjects Withdrawal

The removal of a study subject by the investigator may occur due to the following reasons:

- Study subjects not included: subjects who sign the ICF, but who do not meet the inclusion and non-inclusion criteria of the study;
- Study subjects who present complications affecting their suitability between the signature of the ICF and the beginning of the study;
- Subjects who present - at the Investigator's discretion - any problem that prevent the product applications from continuing, at any time during the study;
- Consent withdrawal by the study subject, regardless of the reason;
- Serious Adverse Event;

- Concurrent disorder or treatment: any pathological process or treatment that occurred during the study period and that might interfere with the study product, such as a medication interaction or masking of results.

Those subjects removed from the study by the Principal Investigator will be supervised in case they present any event possibly related to the study, even after their removal. Those subjects removed due to occurrence of an adverse event will be continually assessed until the case is completely resolved.

Those subjects removed from study after the inclusion stage will not be replaced.

ADVERSE EVENTS

An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a product and that does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the investigational product (adapted from ICH, 2016).

According to the Good Clinical Practices (ICH, 2016), a Serious Adverse Event is any untoward medical occurrence that at any dose

- results in death;
- is life-threatening;
- requires inpatient hospitalization or prolongation of existing hospitalization;
- results in persistent or significant disability/incapacity;
- is a congenital anomaly/birth defect.

Thus, any new sign, symptom or disease, or clinically significant worsening compared to the condition at the first visit, should be considered an Adverse Event. Lack of clinical or self-assessment efficacy of a cosmetic product or drug is not considered an Adverse Event.

Clinical signs and dermatological or systemic diseases observed during the selection process of the study subjects are not considered as Adverse Events. This information is recorded on the medical assessment form as a reason for non-inclusion and the subjects are then not included in the study.

The adverse events occurred as a result of incorrect product use (either cosmetics or drugs products) - such as inappropriate frequency or incorrect application - are considered as adverse events that do not interfere with the product evaluation, since the subject- in this situation - does not follow the correct use directions stated on the product label.

An Adverse Event Form is completed for all events occurred. The study sponsor is notified of an adverse event through a Notification of Occurrence form sent by electronic-mail in the Final Study Report.

In the case of the appearance of Adverse Event in the current study, images of the signs presented by the subjects would be taken, if applicable. In this image the subject's identity will be preserved, and, by signing the informed consent for image release, the subject gave his or her written consented for obtaining and releasing the image.

In case there is an adverse event with doubtful causal nexus, an investigation process is initiated in order to determine if such event is or is not related to the study or investigational product.

The procedures adopted during the event investigation are defined by the physician in charge, based on the nature of the reaction, the subject's medical history and on factors that may interfere with the occurrence of the event, such as medication or other concomitant disorders.

For the conclusion of the final diagnosis, the relation of an Adverse Event can be defined using the decision tree Colipa (2016), according to the following description:

- Very likely: Only cases in which the clinical condition is considered to be evocative will be classified as a very likely nexus, the following conditions occurring together: (i) the temporality of the facts is compatible with an adverse reaction to products and (ii) there is a laboratory test that confirm the relationship with the investigational product (e.g. positive patch test for the investigational product).
- Likely: The cases in which the clinical condition is considered to be evocative will be classified as likely causal nexus, occurring with the following conditions together: (i) the temporality of the facts is compatible with an adverse reaction to cosmetics and (ii) there is no laboratory test to confirm the relationship with the investigational product (e.g. diagnosis of contact dermatitis, without patch test, cosmetic acne - there are no laboratory tests to confirm the relationship with the product).
- Not clearly attributable: Cases in which the clinical scenario is not considered to be evocative or the chronology is not clearly compatible or unknown, will be classified as nexus not clearly attributable.
- Unlikely: The following two cases are associated with an unlikely nexus: the clinical scenario is not considered to be evocative; the chronology is not clearly compatible or unknown, and the result of the investigation with the investigational product is negative (patch test or re-exposure).
- Excluded: The cases in which the diagnosis corresponds to a dermatosis of well-known cause and / or known to be caused by the use of cosmetics will be classified as excluded nexus (e.g. vitiligo, tineas, pityriasis rosea, pityriasis versicolor, psoriasis, folliculitis, solar melanoses, ephelides, among others), when there is no correlation between the subject's complaint and the use of a cosmetic product (for example: muscle pain, lack of appetite, stomach pain, diarrhea, insect bites, among others) or the chronology is clearly incompatible with an adverse reaction to the cosmetic product (for example: there is no improvement in the scenario, even with the interruption of the product; there is relapse of the scenario, without the reintroduction of the product; the signs and symptoms started before the start of the product use).

APPLICABLE ETHICAL REMARKS

The study will be conducted in compliance with the Declaration of Helsinki principles, the applicable regulatory requirements and according to the Good Clinical Practices (Document of the Americas and ICH E6: Good Clinical Practice). This is not an IND / NDA (Investigational New Drug / New Drug Application) clinical trial. IRSI does not assume any Sponsor obligations as stipulated in FDA GCP and ICH documents. This study is not intended for submission to the FDA.

Before the study starts, the subjects will be informed about the study objective, its methodology and length, and about the possibly expected benefits and the constraints related to the study and will sign the Informed Consent Form (ICF), elaborated according to the Declaration of Helsinki and FDA 21 CFR 50.25. The process of obtaining the consent will confirm the voluntary nature of participation in the study.

In order to maintain confidentiality of subjects' data, all data collected will be identified by a number given to them at the beginning of the study. No personal information will be disclosed in all data analysis. If required, the Principal Investigator must allow the study monitor to access all subjects study-related data. This includes all documents containing the subject's clinical history for checking suitability for the study, diagnoses and any other document concerning the subject in the study.

All data to be found or proved by the study results will be considered as being confidential information and sponsor's property. No information - as well as all documents generated during the study - will be copied or disclosed without a previous written consent of the sponsor. All information will be kept confidential until the results were published.

The study technical documentation will be in the Institute’s files, where it will be stored for a 2-year period.

STATISTICAL ANALYSIS

Description of the treatment applied to the data.

Detailed statistical analysis

Data Type	Statistical Method	Data Reported
Subjective Questionnaire	Descriptive Statistics	Response frequency Percent favorable responses

RESULTS/ EXPECTED OUTCOMES

It is expected that the use, under normal conditions, of the investigational product for 2 weeks, demonstrates an improving of the hair thickness, increases shine, reduces frizz, protects hair from heat damage and presents superior technical characteristics to products of the same category.

STUDY TERMINATION

The sponsor has the right to terminate the study at any moment. Reasons that may lead to an early termination of the study are:

- Unsatisfactory inclusion of subjects in the study, with regards to quality and quantity;
- Incidence of incomplete or inappropriate data record;
- Lack of adherence to the protocol;
- Non-compliance of the agreement previously established with the Sponsor by the Principal Investigator;
- Administrative issues;
- Interpretation of the Study Protocol;

The procedures defined in the Protocol will be carefully reviewed in order to ensure that all parties involved in the study fully understand the protocol.

PROTOCOL AMENDMENTS

Any protocol revision must be sent to and approved by the Sponsor before being implemented.

STUDY REPORTS

One topline will be delivered within 10 business days of completion of the study.

One report will be sent, in English, with all study data, within 4 weeks after study completion.

In case of any protocol deviation, the Principal Investigator must communicate the sponsor about any changes that may significantly affect the study conduction, and/or make the risks to the subjects higher.

The final report will comprise the following items: Summary, Introduction, Objective, Investigational Product, Applicable Ethical Remarks, Study Period, Study Subject, Methodology, Statistical Analysis, Results, Conclusion, References and Appendices.

REFERENCES

ASTM, 2006 E 1958-06- Standard Guide for Sensory Claim Substantiation

COLIPA GUIDELINES – Efficacy Evaluation of Cosmetic Products – May 2008.

FDA 21. Code of Federal Regulations (CFR) 50.25., Title 21. Volume1. April, 2019.

FDA 21. Code of Federal Regulations (CFR), Vol. 62, No. 194, 52243. Federal Register, October, 1997.

INTERNATIONAL CONFERENCE FOR HARMONIZATION (ICH) Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance, 1996

ORGANIZACIÓN PANAMERICANA DE LA SALUD. BUENAS PRÁCTICAS CLÍNICAS: Documento De Las Américas, 2005

WORLD MEDICAL ASSOCIATION. Helsinki Declaration: Ethical principles for clinical research involving human beings, 52, 2000. Edinburgh: [y.n.], 2000. Amendment.

APPENDIX B

A. Post-Treatment Questionnaire (Week 2)

Question #1: 1= 0%, 2= 25%, 3= 75%, 4= 100%
Question #9: 1= Very Unlikely, 2= Unlikely, 3= Likely, 4= Very Likely
All Other Questions: 1= Highly Agree, 2= Agree, 3= Disagree, 4= Highly Disagree

ID	1. The SRI DryQ cut my drying time by	2. My hair feels softer after using the SRI DryQ	3. My hair feels stronger after using the SRI DryQ	4. My hair looks and feels fuller after using the SRI DryQ	5. My scalp health improved after using the SRI DryQ	6. I prefer the SRI DryQ over other hair dryers I've used in the past	7. The SRI DryQ doesn't damage my hair like other hair dryers	8. The SRI DryQ is quieter than other hair dryers I've tried in the past	9. How likely would you be to suggest the SRI DryQ to friends and family?	10. I feel more confident drying and styling my hair with the technology the SRI DryQ provides	11. The SRI DryQ helps strengthens weak, brittle, damaged hair	12. The SRI DryQ is easy to use compared to other hair dryers I've used	13. The SRI DryQ gives my hair more volume than other hair dryers	14. I feel more confident after using the SRI DryQ	15. The foldable design makes traveling and storage more convenient than other dryers	16. My hair is shinier after using the SRI DryQ	17. I feel like I just stepped out of the salon after using the SRI DryQ	18. I feel the SRI DryQ is a better product than other hair dryers I've used in the past.	19. Drying my hair is fast and easy with the SRI DryQ	20. The SRI DryQ is the best dryer I've ever used
001	2	3	3	3	3	3	3	3	4	4	3	3	4	3	4	4	3	3	3	3
002	3	2	2	3	2	2	3	4	3	2	2	3	2	3	4	2	2	3	3	2
003	1	2	2	3	2	2	3	2	2	3	2	3	3	2	4	3	2	3	3	2
004	3	3	3	4	3	4	4	4	4	4	4	4	4	4	4	3	3	4	4	4
005	3	4	3	3	3	4	3	3	4	4	3	4	3	3	4	4	3	4	4	3
006	3	3	3	2	3	4	4	4	4	4	3	3	2	3	3	3	2	4	4	4
007	2	3	3	3	2	3	3	3	4	3	3	3	3	3	4	3	3	3	3	3
008	2	2	2	2	2	1	3	3	3	2	3	2	2	2	3	2	2	2	1	2
009	2	4	3	3	3	3	4	4	4	4	4	3	3	3	3	3	4	4	3	3
010	2	3	2	2	2	3	4	4	3	2	3	3	1	2	4	4	2	3	3	2
011	3	4	3	3	4	4	3	4	4	4	3	4	3	3	4	3	3	4	4	4
012	2	3	3	2	3	3	3	4	4	3	3	4	3	3	4	3	3	3	4	3
013	4	4	3	4	3	4	4	4	4	4	3	4	4	3	4	4	4	4	4	4
014	1	2	2	2	2	3	2	2	3	2	2	2	2	2	2	2	2	2	3	2
015	2	3	3	2	3	3	3	3	4	3	3	3	3	3	3	3	3	3	3	2
016	4	4	4	4	3	4	4	4	4	4	3	4	4	4	4	4	4	4	4	4
017	2	3	2	4	3	3	2	2	3	2	3	3	4	4	3	1	2	3	3	2
018	2	3	2	4	2	2	3	4	3	3	2	3	4	3	3	4	2	3	2	2
019	3	2	2	2	2	3	2	3	3	3	2	2	2	2	3	2	2	3	3	3
020	3	2	2	2	3	3	2	4	3	3	2	4	2	2	4	4	2	2	4	2

021	3	3	3	3	2	4	3	3	4	3	3	4	3	3	4	3	2	3	4	3
022	2	3	3	3	3	3	3	3	4	3	3	4	3	4	4	4	4	3	3	3
023	2	3	2	3	2	3	3	4	3	3	2	2	3	3	3	2	2	4	4	3
024	2	3	3	3	2	2	3	2	1	2	3	2	3	3	3	2	2	2	2	2
025	3	3	3	3	3	2	3	4	4	3	2	3	2	3	4	3	2	3	3	3
026	2	1	2	3	2	2	2	4	2	2	1	4	3	3	4	2	2	3	4	2
027	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
028	3	4	3	4	3	4	4	3	4	4	3	3	3	3	4	4	3	3	4	3
029	3	4	3	4	2	4	3	3	4	3	3	3	4	3	4	3	3	3	3	3
030	3	3	3	4	3	4	4	4	4	4	4	4	4	4	4	3	4	4	4	4
031	3	4	3	4	3	4	4	4	4	4	3	4	4	4	4	3	4	4	4	4
032	3	3	3	3	3	4	3	4	4	4	3	3	3	3	4	3	3	4	3	4
033	4	4	4	4	4	4	4	4	4	4	3	3	3	4	4	3	3	3	3	4
034	3	3	2	2	3	2	3	2	3	2	3	2	3	2	3	2	2	3	3	2
035	4	4	3	4	3	4	4	4	4	4	3	4	4	4	4	4	4	4	4	4

DocuSigned by:
Jordan DeSantis
Signer Name: Jordan DeSantis
Signing Reason: I approve this document
Signing Time: 4/6/2022 | 4:10:13 PM PDT
FB54078B585B4ABD9FC0E6F153E03FF8

Jordan Desantis, MHI
Director of Sunscreen Testing

DocuSigned by:
MaryJo Gallegos
Signer Name: MaryJo Gallegos
Signing Reason: I have reviewed this document
Signing Time: 4/6/2022 | 4:13:15 PM PDT
82385AC4BDAF472CACB88B810917EE98

Mary Jo Gallegos
Clinical QA Specialist